Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Revive Therapeutics (RVVTF) Stock Price & Analysis

58 Followers

RVVTF Stock Chart & Stats

$0.01$0.00(7.69%)
At close: 4:00 PM EST
$0.015$0.02$0.025Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.01 - $0.01
52-Week Range
$0.00 - $0.06
Previous Close
$0.01
Volume
N/A
Average Volume (3M)
102.90K
Market Cap
$6.24M
Enterprise Value
$15.30M
Total Cash (Recent Filing)
$14.83K
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
-1.76
Next Earnings
Nov 27, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Debt Burden

Very low debt, including zero total debt in 2026, reduces near-term refinancing pressure and interest obligations. This gives Revive some financial flexibility while its drug candidates remain in development, although the benefit is constrained by negative equity and limited assets.

Narrowing Losses

The significant reduction in losses during 2026 indicates progress toward tighter cost control or a smaller operating footprint. If maintained, this trend could extend the company’s financial runway and reduce the amount of capital required to support ongoing development activities.

Improved Cash Burn

A sharp improvement in operating cash flow suggests that cash consumption has moderated, which can support continuity of research and clinical programs over the next several quarters. The improvement is constructive, even though cash generation remains negative and funding needs continue.

Bears Say

No Commercial Revenue

The absence of revenue leaves Revive without a commercial funding base for its drug-development programs. Persistent dependence on future clinical progress and external capital makes operating performance highly sensitive to financing availability and delays in converting candidates into products.

Negative Shareholders’ Equity

Negative and worsening shareholders’ equity shows that accumulated losses have eroded the company’s capital base. This weakens balance-sheet resilience, limits financial flexibility, and increases the importance of obtaining additional funding while the business remains in development.

Persistent Negative Cash Flow

Consistently negative operating and free cash flow indicates that Revive has not yet funded its activities internally. Even with recent improvement, continued cash burn and no revenue support imply ongoing reliance on external financing to sustain research and clinical development.

Revive Therapeutics News

RVVTF FAQ

What was Revive Therapeutics’s price range in the past 12 months?
Revive Therapeutics lowest stock price was $0.00 and its highest was $0.06 in the past 12 months.
What is Revive Therapeutics’s market cap?
Revive Therapeutics’s market cap is $6.24M.
When is Revive Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Revive Therapeutics’s earnings last quarter?
Revive Therapeutics released its earnings results on Jun 01, 2026. The company reported -$0.001 earnings per share for the quarter.
Is Revive Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Revive Therapeutics pay dividends?
Revive Therapeutics does not currently pay dividends.
What is Revive Therapeutics’s EPS estimate?
Revive Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics have?
Revive Therapeutics has 444,613,950 shares outstanding.
What happened to Revive Therapeutics’s price movement after its last earnings report?
Revive Therapeutics reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Revive Therapeutics?
Currently, no hedge funds are holding shares in RVVTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology